Sequoia Financial Advisors LLC Buys Shares of 1,964 Medpace Holdings, Inc. (NASDAQ:MEDP)

Sequoia Financial Advisors LLC bought a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 1,964 shares of the company’s stock, valued at approximately $602,000.

Several other institutional investors also recently bought and sold shares of the stock. RiverPark Advisors LLC acquired a new stake in shares of Medpace in the fourth quarter valued at about $26,000. Contravisory Investment Management Inc. acquired a new stake in shares of Medpace in the fourth quarter valued at about $26,000. Altshuler Shaham Ltd acquired a new stake in shares of Medpace in the fourth quarter valued at about $27,000. FinTrust Capital Advisors LLC acquired a new stake in shares of Medpace in the third quarter valued at about $30,000. Finally, Rockefeller Capital Management L.P. grew its position in shares of Medpace by 361.3% in the fourth quarter. Rockefeller Capital Management L.P. now owns 143 shares of the company’s stock valued at $30,000 after purchasing an additional 112 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Medpace news, major shareholder Medpace Investors, Llc sold 50,000 shares of the firm’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $391.75, for a total transaction of $19,587,500.00. Following the completion of the transaction, the insider now owns 5,539,947 shares in the company, valued at $2,170,274,237.25. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Medpace news, major shareholder Medpace Investors, Llc sold 50,000 shares of the firm’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $391.75, for a total transaction of $19,587,500.00. Following the completion of the transaction, the insider now owns 5,539,947 shares in the company, valued at $2,170,274,237.25. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO August J. Troendle sold 100,000 shares of Medpace stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $412.98, for a total transaction of $41,298,000.00. Following the completion of the transaction, the chief executive officer now owns 4,833,019 shares of the company’s stock, valued at approximately $1,995,940,186.62. The disclosure for this sale can be found here. Insiders sold a total of 189,340 shares of company stock worth $76,651,647 over the last quarter. Company insiders own 20.30% of the company’s stock.

Medpace Stock Down 0.5 %

MEDP stock opened at $385.05 on Wednesday. The company has a market cap of $11.93 billion, a PE ratio of 43.36, a price-to-earnings-growth ratio of 2.09 and a beta of 1.38. Medpace Holdings, Inc. has a twelve month low of $185.43 and a twelve month high of $419.42. The business’s 50-day simple moving average is $392.28 and its 200 day simple moving average is $318.22.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Monday, February 12th. The company reported $2.46 EPS for the quarter, topping analysts’ consensus estimates of $2.22 by $0.24. The firm had revenue of $498.40 million during the quarter, compared to analysts’ expectations of $498.72 million. Medpace had a net margin of 15.00% and a return on equity of 63.98%. The company’s revenue for the quarter was up 26.5% compared to the same quarter last year. During the same quarter last year, the company earned $2.12 earnings per share. On average, equities research analysts anticipate that Medpace Holdings, Inc. will post 10.53 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on MEDP. Deutsche Bank Aktiengesellschaft initiated coverage on Medpace in a research report on Monday, March 18th. They issued a “hold” rating and a $395.00 price target on the stock. Robert W. Baird lifted their target price on Medpace from $312.00 to $408.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 14th. StockNews.com downgraded Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, March 23rd. Finally, UBS Group raised Medpace from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $282.00 to $452.00 in a research report on Thursday, February 15th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $382.00.

Medpace Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.